Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Assembly Biosciences (ASMB) over the last 11 years, with Q3 2025 value amounting to $2.3 million.

  • Assembly Biosciences' Change in Accured Expenses rose 9702.89% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 47887.32%. This contributed to the annual value of $1.4 million for FY2024, which is 16204.74% up from last year.
  • Assembly Biosciences' Change in Accured Expenses amounted to $2.3 million in Q3 2025, which was up 9702.89% from $1.1 million recorded in Q2 2025.
  • Assembly Biosciences' 5-year Change in Accured Expenses high stood at $2.4 million for Q4 2024, and its period low was -$8.3 million during Q1 2021.
  • Over the past 5 years, Assembly Biosciences' median Change in Accured Expenses value was $1.1 million (recorded in 2025), while the average stood at -$347105.3.
  • As far as peak fluctuations go, Assembly Biosciences' Change in Accured Expenses crashed by 13178.95% in 2023, and later surged by 49006.62% in 2024.
  • Assembly Biosciences' Change in Accured Expenses (Quarter) stood at $1.4 million in 2021, then rose by 15.49% to $1.6 million in 2022, then fell by 27.32% to $1.2 million in 2023, then skyrocketed by 98.57% to $2.4 million in 2024, then fell by 1.94% to $2.3 million in 2025.
  • Its Change in Accured Expenses was $2.3 million in Q3 2025, compared to $1.1 million in Q2 2025 and -$4.6 million in Q1 2025.